Risk factors for acute kidney injury in vancomycin and piperacillin/tazobactam combination therapy: A retrospective study
| Autor: | Wataru Shibata, Katsuya Nagayama, Hiroshi Kakeya, Koichi Yamada, Yuma Yamashita, Hiroshi Kawaguchi, Yasutaka Nakamura, Norihiro Sakurai, Kazuhiro Oshima, Takumi Imai, Tsubasa Yano |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Combination therapy Penicillanic Acid urologic and male genital diseases Tazobactam Risk Factors Vancomycin Internal medicine medicine Humans Pharmacology (medical) Retrospective Studies Piperacillin urogenital system business.industry Acute kidney injury Retrospective cohort study Odds ratio Acute Kidney Injury medicine.disease female genital diseases and pregnancy complications Anti-Bacterial Agents Piperacillin Tazobactam Drug Combination Infectious Diseases Concomitant Piperacillin/tazobactam Drug Therapy Combination business medicine.drug |
| Zdroj: | Journal of Infection and Chemotherapy. 27:1614-1620 |
| ISSN: | 1341-321X |
| Popis: | Introduction Combined use of vancomycin (VCM) and piperacillin/tazobactam (PIPC/TAZ) has been reported to increase the incidence of acute kidney injury (AKI). However, the risk factors associated with AKI after VCM and PIPC/TAZ (VPT) administration have not yet been identified. Therefore, we retrospectively assessed patients treated with VPT to investigate the risk factors for AKI development. Methods The study involved patients who were treated with VPT from January 1, 2016 to March 31, 2020. The patients were divided into the AKI or non-AKI group. The clinical characteristics of patients and antimicrobial therapy were compared between the groups. Their association with AKI risk was evaluated using multivariate logistic regression analysis. Results In total, 182 patients were included, with 118 in the non-AKI group and 64 in the AKI group. Therefore, the incidence of AKI was 35.2 %. The initiation of VPT combination therapy on the same day and concomitant use of vasopressors were associated with an increased risk of AKI (odds ratio [OR] 2.55, 95 % confidential interval [CI] 1.20–5.44 and OR 3.22, 95 % CI 1.31–7.89, respectively). Conclusion Our findings suggest that the concomitant use of vasopressors and initiating VPT combination therapy on the same day are likely risk factors for AKI development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect